Commentary: Triptan use during pregnancy: a safe choice?
Kurth
Tobias
T
From the Institut national de santé et de recherche médicale (INSERM), Unit 708 - Neuroepidemiology, Paris, France.
Hernandez-Diaz
Sonia
S
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D015982:Bias; D015984:Causality; D002561:Cerebrovascular Disorders / Q000139:chemically induced / Q000453:epidemiology; D015897:Comorbidity; D003627:Data Interpretation, Statistical; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005260:Female; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy; D009664:Norway / Q000453:epidemiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced* / Q000453:epidemiology*; D011261:Pregnancy Trimester, First / Q000187:drug effects; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced* / Q000453:epidemiology*; D012042:Registries; D015203:Reproducibility of Results; D018570:Risk Assessment; D012307:Risk Factors; D014363:Tryptamines / Q000009:adverse effects*
D014363:Tryptamines